Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A, Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G, Francini G. Correale P, et al. Br J Cancer. 2004 May 4;90(9):1710-4. doi: 10.1038/sj.bjc.6601783. Br J Cancer. 2004. PMID: 15150625 Free PMC article. Clinical Trial.
Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb.
Caraglia M, Tagliaferri P, Correale P, Genua G, Pinto A, Del Vecchio S, Esposito G, Bianco AR. Caraglia M, et al. Among authors: correale p. Cancer Immunol Immunother. 1993 Aug;37(3):150-6. doi: 10.1007/BF01525428. Cancer Immunol Immunother. 1993. PMID: 8392910 Free PMC article.
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.
Tagliaferri P, Barile C, Caraglia M, Guarrasi R, Morelli D, Ricciardi B, Martignetti A, Librera MT, Matano E, Della Vecchia A, Catalano G, Famiani M, Palmieri G, Correale P, Bianco AR. Tagliaferri P, et al. Among authors: correale p. Am J Clin Oncol. 1998 Feb;21(1):48-53. doi: 10.1097/00000421-199802000-00011. Am J Clin Oncol. 1998. PMID: 9499257 Clinical Trial.
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.
Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G, Francini G. Correale P, et al. Eur J Cancer. 2001 May;37(7):892-902. doi: 10.1016/s0959-8049(01)00063-6. Eur J Cancer. 2001. PMID: 11313178 Clinical Trial.
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G. Correale P, et al. Br J Cancer. 2001 Nov 30;85(11):1722-30. doi: 10.1054/bjoc.2001.2136. Br J Cancer. 2001. PMID: 11742494 Free PMC article.
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma.
Francini G, Petrioli R, Gonnelli S, Correale P, Pozzessere D, Marsili S, Montagnani A, Lucani B, Rossi S, Monaco R, Manganelli A, Salvestrini F, Fiaschi AI. Francini G, et al. Among authors: correale p. Cancer. 2001 Sep 15;92(6):1468-74. doi: 10.1002/1097-0142(20010915)92:6<1468::aid-cncr1471>3.0.co;2-s. Cancer. 2001. PMID: 11745224
168 results